JANX
Janux Therapeutics, Inc.
+0.74 (+4.59%)16.99USD209K成交股數1.0B市值–本益比(近四季)43.3股價營收比–營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 10.3M | 3.7M | 0.00-100% | 10.0M+12% | 0.00-100% | 0.00-100% | 439K-83% | 8.9M+742% | 1.3M | 2.5M | 2.5M | 1.1M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 31.0M | 26.8M | 31.5M | 34.6M | 34.7M | 25.1M | 18.6M | 14.9M | 14.1M | 12.2M | 11.9M | 14.9M |
| 銷售管理費用 | 11.0M | 11.1M | 10.9M | 10.6M | 10.5M | 9.8M | 17.7M | 7.8M | 7.3M | 6.4M | 6.4M | 6.9M |
| 營業利益 | −31.7M-30% | −34.2M-2% | −42.4M+18% | −35.3M+155% | −45.1M+124% | −34.9M+116% | −35.8M+127% | −13.8M-33% | −20.2M | −16.1M | −15.8M | −20.7M |
| 營業利益率 | -308.7% | -916.5% | – | -352.5% | – | – | -8,164.5% | -155.4% | -1,610.3% | -655.7% | -628.2% | -1,962.9% |
| 稅後淨利 | −22.0M-35% | −24.4M+4% | −31.9M+14% | −24.3M+308% | −33.9M+129% | −23.5M+100% | −28.1M+143% | −6.0M-66% | −14.8M | −11.8M | −11.6M | −17.5M |
| 淨利率 | -214.0% | -652.6% | – | -243.1% | – | – | -6,391.6% | -67.0% | -1,178.9% | -477.8% | -459.6% | -1,656.4% |
| 稀釋 EPS | -0.35-36% | -0.39+3% | -0.510% | -0.39+255% | -0.55+83% | -0.38+65% | -0.51+104% | -0.11-74% | -0.30 | -0.23 | -0.25 | -0.42 |
| 稀釋股數 | 62.9M | 62.7M | 62.0M | 62.0M | 61.9M | 61.8M | 54.6M | 54.5M | 49.0M | 44.0M | 45.7M | 41.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 27.8M | 51.8M | 52.3M | 48.4M | 52.4M | 73.7M | 26.8M | 14.7M | 213M | 19.2M | 17.2M | 33.7M |
| 應收帳款 | 149K | 35.0M | 0.00 | – | – | – | – | 7.5M | 519K | 0.00 | 0.00 | 0.00 |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B | 1.1B | 695M | 691M | 689M | 380M | 387M | 342M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 79.7M | 86.7M | 44.7M | 48.2M | 41.7M | 38.3M | 38.9M | 33.7M | 33.2M | 36.1M | 37.9M | 42.0M |
| 股東權益 | 928M | 942M | 957M | 977M | 991M | 1.0B | 656M | 658M | 656M | 344M | 349M | 299M |
| 負債比 | 7.9% | 8.4% | 4.5% | 4.7% | 4.0% | 3.6% | 5.6% | 4.9% | 4.8% | 9.5% | 9.8% | 12.3% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −12.3M-28% | – | – | – | −17.0M | – | – | −14.8M | – | – | – |
| 資本支出 | – | 273K | – | – | – | 371K | – | – | 197K | – | – | – |
| 自由現金流 | – | −12.6M-28% | – | – | – | −17.4M | – | – | −15.0M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -337.8% | – | – | – | – | – | – | -1,200.8% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 10.0M | -5.6% | −114M | -1,136.3% | -1.83 | −83.3M |
| FY2024 | 10.6M | +31.0% | −69.0M | -651.6% | -1.28 | −44.2M |
| FY2023 | 8.1M | -6.1% | −58.3M | -721.2% | -1.32 | −52.4M |
| FY2022 | 8.6M | +136.8% | −63.1M | -732.2% | -1.52 | −49.4M |
| FY2021 | 3.6M | – | −32.7M | -898.3% | -1.39 | −18.5M |
| FY2020 | 0.00 | – | −6.8M | –% | -7.41 | −4.4M |